{
  "id": 16744315,
  "title": "Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline",
  "url": "https://urgent.news/2026/10/27/teva-acquires-worldwide-rights-to-bxcl501-further-expanding",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-27T12:03:04.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/teva-acquires-worldwide-rights-to-bxcl501-further-expanding-innovative-neuroscience-pipeline"
  },
  "original_language": "en",
  "account": null,
  "summary": "BXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Acquisition adds differentiated late-stage investigational asset with potential to address a significant unmet need for patients Transaction supports Teva’s Pivot to Growth strategy and the […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}